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ABSTRACT
Hygromycin A (HygA) binds to the large ribosomal
subunit and inhibits its peptidyl transferase (PT) ac-
tivity. The presented structural and biochemical data
indicate that HygA does not interfere with the ini-
tial binding of aminoacyl-tRNA to the A site, but pre-
vents its subsequent adjustment such that it fails
to act as a substrate in the PT reaction. Structurally
we demonstrate that HygA binds within the peptidyl
transferase center (PTC) and induces a unique con-
formation. Specifically in its ribosomal binding site
HygA would overlap and clash with aminoacyl-A76
ribose moiety and, therefore, its primary mode of ac-
tion involves sterically restricting access of the in-
coming aminoacyl-tRNA to the PTC.
INTRODUCTION
Hygromycin A (HygA) is a natural product of Streptomyces
hygroscopicus first isolated in 1953 (1,2). It is endowed with
promising biological activities and has a unique structure
(Supplementary Figure S1) consisting of a furanose, cin-
namic acid and aminocyclitol moiety (3). The biosynthetic
pathway ofHygAhas been elucidated (4) and its total chem-
ical synthesis has also been described (5–7). HygA has a
relatively broad antimicrobial spectrum, displaying activity
against gram-positive bacteria including mycobacteria and
actinomycetes (3). In addition this molecule is also active
against Serpulina (Treponema) hyodysenteriae (the agent of
swine dysentery), leptospira and endomoeba (1,3). The lim-
ited activity of HygA against enteric gram-negative bacteria
has been attributed to the efficient AcrA/B efflux pump op-
erating in these organisms (8).
The structure and biological activity of HygA are distinct
from those of hygromycin B, another antibiotic produced
by the same organism, but HygA displays some common
features with chloramphenicol (1–3) and orthoformimycin
(9). HygA was shown to be a translational inhibitor; or
more precisely, HygA was found to bind to the large (50S)
ribosomal subunit and to inhibit the peptidyl transferase
(PT) activity of the ribosome (10–12). Other translational
steps, such as the enzymatic (EF-Tu dependent) binding of
aminoacyl-tRNA to the ribosomal A site and the transloca-
tion of peptidyl-tRNA from the A to the P site were found
to be unaffected by HygA (10). Furthermore, since HygA is
a more potent agent than chloramphenicol and inhibits ri-
bosomal binding of chloramphenicol, it was suggested that
the binding sites of these two antibiotics are close or par-
tially overlapping (10).
A structural similarity has been observed between HygA,
A201A and puromycin (4,13–17). More precisely, the 6′-7′-
dihydroxy--methylcinnamic acidmoiety ofHygA (Supple-
mentary Figure S1) and the 7′-hydroxy--methylcinnamic
acid present in A201A are similar to the tyrosine-derived
moiety of puromycin (4).
Similar to HygA, both A201A and puromycin are po-
tent inhibitors of protein synthesis and all three antibiotics
prevent peptide bond formation (10,13,17–20). Puromycin,
the best characterized of the three antibiotics, binds, as do
HygA and chloramphenicol, to the A site of the large sub-
unit where it structurally mimics the aminoacyl-tRNA 3′
terminus and can serve as an acceptor of the polypeptide
chain via the 2′ amino group (21,22).Moreover, in its higher
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affinity form of CC-puromycin, it can induce on the large
subunit, the same active conformation of the PTC, as ob-
served on the complete 70S ribosome (22–26). Despite the
similarity between the three antibiotics, and in contrast to
puromycin, both HygA and A201A do not carry at the 2′
position a reactive amino group ((17) and Supplementary
Figure S1) and therefore cannot act as acceptor substrates
in peptide bond formation.
In situ chemical probing showed that macrolides with a
mycarose containing disaccharide at position 5 of the lac-
tone ring, such as, carbomycin, tylosin and spiramycin, in-
hibit or compete with HygA for ribosomal binding. On the
other hand, HygA can bind to the ribosome concomitantly
with macrolides that have only a monosaccharide exten-
sion on the lactone ring and do not inhibit the PT reac-
tion (11). Overall, the available data indicate that although
HygA binds to the ribosome in a region that overlaps that of
other 50S-targeting antibiotics, its binding mode is clearly
distinct.
In light of these data and the frequent occurrence of
resistance and cross-resistance phenotypes acquired by
pathogenic bacteria to 50S-targeting antibiotics, the use of
HygAas a pharmacophore for the development of new anti-
infectives capable of overcoming existing resistance mecha-
nisms, requires a precise knowledge of the relationship be-
tween the binding site of HygA and that of chlorampheni-
col and other 50S inhibitors, the macrolides in particular.
In this study we used a combination of X-ray crystallogra-
phy and biochemical approaches to address the ribosomal
localization of HygA and describe its relationship to other
anti-infectives. Taken together the structural and biochemi-
cal data presented indicate that HygA binds within the PTC
such that it would clash with the aminoacyl-ribosyl moiety
at the 3´end of theA-site tRNA.Therefore its primarymode
of action involves blocking the accommodation of the A-
site tRNA within the PTC. At the same time HygA induces
conformational changes in functionally important residues
of the PTC, which perturb the active site conformation and
may have a secondary role in HygA’s inhibitory mechanism.
MATERIALS AND METHODS
Biochemical assays
In vitro mRNA translation (driven by 027IF2Cp(A)
mRNA) and tests of individual translational steps (e.g. Phe-
tRNAbinding to the ribosomal A site, fMet-puromycin for-
mation and dipeptide (fMet-Phe) formation) were carried
out as described (27,28). In situ probing of the 23S rRNA
by hydroxyl radical cleavage was carried out as described
(29). EF-Tu-dependent A-site binding of proflavine-labeled
Phe-tRNA to MFmRNA-programmed 70S ribosomes car-
rying P-site bound fMet-tRNA (70S IC), was carried out in
the absence or presence of 20 MHygA as described (30).
X-ray crystallography
Crystals of the 50S ribosomal subunit from Deinococcus
radiodurans were prepared as previously described (31,32),
soaked overnight in a stabilizing solution with or without
20 M HygA and flash-frozen in liquid nitrogen. X-ray
diffraction data were collected with a PILATUS detector
at the X06SA beamline at the Swiss Light Source (Villigen,
Switzerland), and processed to 2.9 A˚ and 3.0 A˚ for the com-
plex and apo structures, respectively, using the XDS (33)
and CCP4 (34) program packages. A previously reported
structure of theD. radiodurans 50S subunit (PDB accession
code: 2ZJR) (35) was fully refined against the newly col-
lected data set for the native 50S subunit, and the result-
ing model was used to phase the 50S–HygA complex with
Phenix (36). The same set (∼5%) of the reflections data was
omitted during refinement for the free R factor calculation.
The binding position of the drug was determined based
on A-weighted difference maps (37). Electron density in-
dicating the presence of HygA and alterations in nearby
nucleotides was unambiguously observed in the A site of
the PTC in the initial unbiased electron density maps ob-
tained with G2061, A2451-C2452, A2503-C2507, A2572-
C2573, G2583-U2585 and A2602 excluded from calcula-
tion (Supplementary Figure S2). Although the positions of
the phenol-, alkene- and peptide moieties within the HygA
structure suggest a conjugated system, with a preferential
continuous planarity in solution along the C1′–C4′ back-
bone of HygA, during model refinement three separate pla-
narity restraints for each of these moieties were created.
This resulted in small violations (<10◦) in the planarity of
the system, possibly due to the specific chemical environ-
ment of the ribosome, which can affect the mesomerism of
the conjugated system (i.e. along the C1′–C4′ atoms, Sup-
plementary Figure S1). Concerning the aminocyclitol moi-
ety, during refinement either no torsion restraints for this
moiety were active or torsion restraints were present to
support either a chair or twisted boat conformation; the
aminocyclitol moiety of HygA has been reported to acquire
a twisted boat conformation in solution (38). Independently
from the applied setup the models always converged to the
same final model with a chair like conformation. Compared
to the twisted boat conformations, the chair like conforma-
tion also fits best the density of the unbiased map or the
2Fo–Fc map obtained imposing the twisted boat confor-
mation through out the refinement. Modeling and refine-
ment were carried out using Coot (39) and Phenix (36).
rRNA nucleotide suites were thoroughly corrected using
ERRASER (40) and RCrane (41). Chemical structures of
HygA and relevant compounds were depicted using Mar-
vinSketch (ChemAxon: http://www.chemaxon.com). Coor-
dinates and restraints of the drug suitable for refinement
were obtained using the GRADE server (42) and eLBOW
(43). rRNA residues were numbered according to the Es-
cherichia coli scheme and helices indicated using the stan-
dard nomenclature.
RESULTS
HygA binds in the A site of the peptidyl transferase center
and alters its conformation
To elucidate the molecular mechanism of action of HygA
we first determined its ribosomal binding site using X-ray
crystallography. The initial unbiased map clearly showed
extra electron density in the A site of the peptidyl trans-
ferase center (PTC; Supplementary Figure S2). Its elon-
gated shape with prominent densities at either end al-
lowed unambiguous assignment of the terminal furanose
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Figure 1. The HygA binding site. (A) An overview showing the location of HygA (colored in magenta) on the Deinococcus radiodurans 50S ribosomal
subunit. (B) The HygA binding site is formed by 23S rRNA helices H90 and H93 (light and dark green, respectively) and the PTC central loop (orange).
(C and D) Final 2Fo-Fc electron density map sharpened, contoured at 1 sigma and shown from two different perspectives.
and aminocyclitol groups and the subsequent placement of
the central cinnamic acid moiety. Moreover, by comparison
with the native 50S structure conformational changes in 23S
rRNA residues were also detected in the proximity of HygA
(Supplementary Figure S2). The altered nucleotides, includ-
ing U2506, U2585 and A2602, were remodeled and the re-
sulting structure refined to convergence with a final resolu-
tion of 3.0 A˚ (Table 1; final 2Fo–Fc map seen in Figure 1C
and D). As seen in Figure 1, HygA binds in a pocket delim-
ited by A2503, the G2061-A2451 and C2452-U2504 base
pairs, and the G2505-U2506 segment. The rRNA residues
comprising this binding pocket are universally conserved
(>98% conservation) and, therefore, presumably similar
across species. Toward the bottom of the pocket (i.e. near
the ribosomal tunnel) the two hydroxyl groups of the fu-
ranosyl moiety potentially hydrogen bond with nucleotides
A2503 and G2505, apparently serving as anchoring points
for this moiety. On the contrary, the acetyl group on the fu-
ranose ring protrudes into the lumen of the ribosomal tun-
nel and, therefore, makes no significant interactions with
the ribosome (Figures 1C-D and 2C). The central cinnamic
acid moiety stacks against the walls of the pocket, namely
the G2061-A2451 and C2452-U2504 base pairs, with the
C6′ hydroxyl group of HygA within hydrogen-bonding dis-
tance of the O2′ and O3′ of G2505 (Figures 1C-D and 2A–
C). In addition, the C1′ carboxyl oxygen, in the cinnamic
acid moiety, is within hydrogen bonding distance of both
the 2′-OH of A2451 and the N6 of A2602 (Figure 2A and
C). The aminocyclitol moiety is positioned at the entrance
of the binding pocket. In this moiety, the oxygen atoms at
positions 5 and 6 potentially hydrogen bond with the N4 of
C2573, while its amide nitrogen at position 2 and hydroxyl
oxygen at position 3 could form hydrogen bonds with the
O2 of U2506 and O4 of U2585, respectively (Figure 2A and
C).
Comparing the structures of the PTC’s A site in the pres-
ence and absence of HygA, reveals that HygA binding in-
duces conformational changes in functionally important
PTC nucleotides (Figure 2B). Namely, in the presence of
HygA, U2506 and U2585 are shifted and interact, form-
ing a non-canonical Watson–Crick base pair with their N3
and O4 positions alternately hydrogen-bonded (Figure 2A
and C, green dotted lines; Supplementary Figure S2C and
D). The formation of the U2506 and U2585 base pair in
the presence of HygA is in good agreement with chemi-
cal probing experiments showing that in the presence of
HygA the N3 of both U2585 and U2506 are protected from
modification (11). A similar base pair is observed when
homoharringtonine, a eukaryotic specific anti-tumorigenic
compound targeting the A-site, is bound to the Haloar-
cula marismortui 50S subunit (44). Furthermore, A2602 is
disordered in the native structure (50S apo) but its den-
sity becomes more evident in the presence of HygA (Fig-
ure 1C and D, Supplementary Figure S2C and D) which
likely reflects that it is more stably positioned. Accordingly,
our model places the extracyclic amine of A2602 within hy-
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Figure 2. HygA-dependent perturbations in the PTC. (A) The structure of the PTC’s A-site in the presence of HygA (50S–HygA). In the 50S–HygA
complex nucleotides critical for tRNA binding acquire a unique conformation. Potential hydrogen bonds between HygA and the 23S rRNA are indicated
in orange and those newly formed solely within the 23S rRNA are green. (B) An overlay of the 50S–HygA (blue) and apo-50S (yellow) structures with the
significant displacements of U2506, U2585 and A2602 indicated with arrows. The position of the A2602 base in the apo-50S structure is only indicative as
this residue is very dynamic in the absence of the drug while it acquires a more stable conformation in the presence of HygA. (C) A schematic representation
of the potential interactions formed between HygA and 23S rRNA residues that are predicted on the basis of geometric constrains. Potential hydrogen
bonds between HygA and the 23S rRNA are indicated with black arrows and HygA dependent hydrogen bonds formed within the 23S rRNA are indicated
with green arrows. The stacking interaction between the C2452, the cinnamic acid moiety and A2451 are indicated with green and purple circles. Note the
orientation of the drug in D is mirrored relative to panels A–C.
drogen bonding distance of the carboxyl oxygen of the cin-
namic acid moiety (Figure 2A–C). Taken together, the X-
ray crystallographic analysis indicates that upon binding to
the A-site of the PTC, HygA influences the conformation
of several nucleotides (i.e. A2602, U2585, U2506) that play
critical roles in various stages of translation including po-
sitioning the A and P-site tRNAs during peptide bond for-
mation and translocation (25,26,45).
A structural alignment of the PTC residues in the 50S–
HygA structure with those from structures containing a
bound A-site aminoacyl tRNA substrate (25) clearly show
that the aminocyclitol and cinnamic acid groups of HygA
would overlap and sterically clash with the A76 ribose and
aminoacyl moiety, respectively, of the A-site substrate (Fig-
ure 3A). This structural alignment also makes it evident
that despite the presence in HygA of the aminocyclitol and
furanose moiety, which are absent in the A76-aminoacyl
tRNA, the portion of HygA that shares a structural simi-
larity with puromycin ((4); highlighted atoms in Figure 3C
and F) and thereby also with the A76-aminacyl moiety of
the A site tRNA, is similarly located in the two complexes
(Figure 3A and B). More specifically, the chemical back-
bone of HygA, comprised by the three hydroxyl, C2 posi-
tion and two amino of the aminocyclitol group along with
the cinnamic acidmoiety ofHygA, are similarly located and
structurally resemble on the 50S–HygA complex, the 2′ hy-
droxyl and 3′ amino moiety of the A-site tRNA terminal
ribose (A76) and the phenylalanine amino acid residue, of
the A-site tRNA on the 70S complex (Figure 3A and B).
Moreover, these two related moieties, present in HygA and
the A76-aminoacyl tRNA, also establish a network of in-
teractions with the same surrounding ribosomal elements
i.e. residues A2451, A2602, U2585 and U2506 (Figure 3C–
F). For example, the hydroxyl oxygen at position 3 of the
aminocyclitol moiety potentially forms a hydrogen bond
with O4 of U2585 (Figure 3E and F) similar to that made
by the 2′-OH of the A76 of the A-tRNA (Figure 3C andD).
Likewise the carboxyl oxygen in the cinnamic acid moiety is
located in H bonding distance to both the 2′ OH of A2451
and the N6-amine of A2602 (Figure 3E and F), similar to
the carboxyl oxygen of the A-site bound aminoacyl moiety
(Figure 3C and D).
Despite the chemical similarity of the interactions ob-
served, they differ in their precise spatial arrangement be-
cause HygA alters the conformation of 23S nucleotides
(U2585, U2506) and itself does not enter as deeply into the
A-site, particularly the aminocyclitol moiety, as a fully ac-
commodated A-site substrate (25). Namely it appears that
the U2585–U2506 base pair and the conformation of the
aminocyclitol moiety prevents HygA from being accom-
modated exactly like an aminoacyl tRNA (Figure 3A and
B). Given the chemical similarity between HygA and the
aminoacyl-tRNA, the PTC state observed in the presence of
HygA could be characteristic of a canonical state acquired
as the aminoacyl-tRNA enters or leaves the A-site that is
trapped and exploited by HygA to inhibit protein synthe-
sis or it could be an off-pathway state induced only by the
drug.
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Figure 3. The binding site of HygA on the ribosome overlaps with that of the aminoacyl-A76 ribosyl moiety of the A-site tRNA. (A) The 50S–HygA
HygA–5 complex was aligned to a 70S ribosome with an accommodated A-site (PDB accession code: 4QCP; (25)) using 23S rRNA residues 2063–2092,
2227–2258, 2435–2457 and 2494–2608 showing that the aminoacyl-A76 ribosyl moiety at the acceptor end of the A-site tRNA (yellow) overlaps with the
binding site of HygA (magenta). In (B) only HygA and the aminoacyl-A76 ribosyl moiety from the aligned structures (panel A) are shown to highlight
their similarity. When aligned using PTC residues (as shown in A) the 15 atoms spanning from the 3-hydroxyl to C7’ position of HygA (Supplementary
Figure S1) and their counterparts in the A-site tRNA (indicated by highlights in the chemical structures shown in panels C and F) have a root mean
square deviation (RMSD) of 1.57 A˚. When these 15 atoms are directly aligned on themselves they have a RMSD of 0.86 A˚. Both the aminoacyl moiety
of the A-site tRNA (C and D) and HygA (E and F) appear to be coordinated by a similar hydrogen bond network that includes the 23S rRNA residues
A2451 (via 2′-OH of the ribose), U2506 (2′-OH of the ribose in the acylated tRNA and O2 of the base in the 50S–HygA structure) and A2602 (via the N6
amino group) while U2585 in the 50S–HygA complex is kept at a position similar to that seen in PDB accession code: 4QCP (25) by forming a symmetric
4-carbonyl-N3 U-U pair with residue U2506. The carbonyl carbon present in both ligands is labeled as C’. Note that in a native aminoacyl-tRNA an ester
oxygen rather than an amide nitrogen links the aminoacyl moiety to the tRNA (this position is indicated by an asterisk in panels B, C and F) that can serve
as a proton acceptor only. However, an analogous hydrogen bond between the ester oxygen and U2506 can be formed if the uridine moiety is in the enol
form having a hydroxyl group at position 2 acting as proton donor toward the electron pair of the aminoacyl ester oxygen.
HygA binding induces structural changes not only in proximal
nucleotides but also in distal helices that connect the PTC to
the GTPase associated region
Hydroxyl radical rRNA cleavage of E. coli 70S ribosomes
bound to HygA supports the description of the HygA bind-
ing site presented above.While alteration in the reactivity of
A2453, A2572, G2574, G2576 and G2581 (Figure 4A and
B) can be explained by their proximity to the HygA bind-
ing site (Figure 4C and D), unexpectedly, additional nu-
cleotides in more distant regions were also affected, indicat-
ing that HygA binding caused long-range conformational
changes in the 23S rRNA. The affected nucleotides cluster
in specific regions of H89, H90 and H92/92a (Figure 4D).
These helices stem from the central loop region of domain
V of the 23S rRNA, where the PTC and thus HygA and
the aminoacyl moiety of the A-site tRNA are located, and
reach the GTPase associated region (GAR; H43/H44, H95
and the ribosomal proteins L11, L10 and L7/L12) which
influences the GTPase activity of translational factors such
as the elongation factors EF-Tu and EF-G (Figure 4 D).
Helices, H89/H90-H92, also form the aa-tRNA accom-
modation corridor, which the aminoacyl tRNA transits as it
is accommodated into the PTC (46). This corridor presents
several steric barriers, which recent simulations suggest the
tRNA navigates by following multiple PTC entry pathways
and the selection of these pathways could be influenced by
the conformation of the PTC (46).
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Figure 4. The effect of HygA on the accessibility of the 23S rRNA to hydroxyl radical cleavage. Primer extension analyses was used to define the in situ
cleavage pattern of the (A) 2450 and (B) 2550 regions in the absence (lane 1) or presence of 10 M (lane 2) and 100 M (lane 3) HygA. The lanes marked
G and A are sequencing lanes and lane K contains the control 23S rRNA sample not subjected to cleavage. (C and D) The nucleotides whose accessibility
was decreased (blue) or increased (red) by HygA are shown in relation to the entire 50S ribosomal subunit (C) and more closely (D) where specific residues
and rRNA helices are labeled. Further details are given in ‘Materials and Methods’ section.
HygA allows aminoacyl-tRNA binding to the ribosome but
perturbs its subsequent adjustment that allows it to act as a
PT substrate
The crystallographic data obtained in this study indicate
that HygA binds within the PTC and thereby occludes the
aminoacyl-A76 ribose moiety from the catalytic site (Fig-
ure 3). Accordingly, experiments were carried out to deter-
mine to which extent this competition affects the binding of
the entire aminoacyl-tRNA to the ribosome. As seen from
the results presented in Figure 5A HygA does not inhibit
EF-Tu-dependent binding of Phe-tRNA to poly(U) pro-
grammed 70S ribosomes even in the presence of high HygA
concentrations when measured by nitrocellulose filtration
which assesses the association of the tRNA with ribosome.
In comparison, similar concentrations of the known 30S A-
site inhibitor, tetracycline, caused almost complete inhibi-
tion of the binding (Figure 5A). This finding is in agreement
with the results of a previous study (10). However, when
the A-site binding was followed by stopped-flow kinetics
using fluorescently labeled Phe-tRNAphe (Prf16/17) (Fig-
ure 5B), which reflects not only tRNA binding but also its
chemical environment, a clear effect of HygA was detected.
In fact, unlike in the control samples in which the fluores-
cence intensity of the labeled tRNA increases and then de-
creases reflecting an initial binding of the ligand followed
by its adjustment on the ribosome, the latter adjustment
step was not observed in the samples containing HygA, as
the fluorescence intensity remained high (Figure 5B). To-
gether these findings indicated that whereas HygA does not
completely prevent tRNA binding to the A site it prevents
the tRNA from reaching a fully accommodated state. In
agreement HygA inhibits the PT reaction when assayed us-
ing both natural amino acid substrates (fMet and Phe) as
well as the aminoacyl mimic, puromycin (Figure 5C and
D) (10). The HygA dose-response curves show that inhi-
bition of mRNA translation and dipeptide formation are
superimposable (Figure 5C) indicating that inactivation of
the PT activity can fully account for the block of mRNA
translation caused by this antibiotic. NamelyHygA appears
to be a powerful inhibitor of PT activity, binding tightly
to the ribosome with respect to canonical A-site substrates
and effectively blocking both the specific PT assay and the
more general mRNA translation assay possibly from the
first peptide bond that yields the ‘initiation dipeptide’. This
could explain why the dose response curves for the inhibi-
tion of mRNA translation and dipeptide formation are es-
sentially superimposable. This premise is supported by the
observation of Guerrero and colleagues that HygA once
bound to the ribosome cannot easily be washed away by su-
crose gradients or gel filtration chromatography (10). The
binding of HygA into the PTC is further indicated by the
observation that HygA competes with the known A-site
binding antibiotic chloramphenicol (Figure 6A; (10)) but
it responds differently to a 23S rRNA mutation (G2061A)
(47) that confers resistance to chloramphenicol. Namely
an in vitro translation assay that utilizes ribosomes har-
boring the G2061A mutation (47) is sensitive to CAM but
not HygA (Figure 6B). These results support the crystallo-
graphic studies that indicate HygA primarily interferes with
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Figure 5. The effect of HygA on aminoacyl-tRNA binding to the A-site,
transpeptidation and mRNA translation. (A) The EF-Tu and poly(U)-
dependent binding of Phe-tRNA to the A site of Escherichia coli 70S ribo-
somes is shown as a function of increasing concentrations of HygA (black)
or tetracycline (green). (B) The kinetics of EF-Tu-dependent A-site bind-
ing of proflavine-labeled Phe-tRNA toMFmRNA-programmed 70S ribo-
somes carrying P-site bound fMet-tRNA in the absence (red tracing) and
presence (black tracing) of 20 Mof HygA. The binding kinetics were fol-
lowed in a fluorescence stopped-flow apparatus. Further details are given
in ‘Materials and Methods’ section. (C) Dose-response of hygromycin A
inhibition of in vitromRNA translation (red) and fMet-Phe dipeptide for-
mation (black). (D) Time course of fMet-puromycin formation in the ab-
sence (black) or presence (red) of 20 Mof hygromycin A. Further details
are given in ‘Materials and Methods’ section.
Figure 6. (A) Hygromycin A––chloramphenicol competition for binding
to the 50S ribosomal subunit. Release of 50S ribosomes-bound [14C]-
chloramphenicol upon addition of increasing concentrations of HygA.
Further details are given in ‘Materials and Methods’ section. (B) Com-
parison of the inhibitory activities of HygA (blue) and chloramphenicol
(black) on 027 mRNA translation in a cell free extract of a Thermus ther-
mophilus mutant (23S rRNA G2061A; (47)).
the accommodation of the aminoacyl-tRNA’sCCAend (ac-
ceptor domain) into the PTC thus blocking the PT reaction.
DISCUSSION
The present crystallographic localization of HygA on the
50S ribosomal subunit together with the biochemical data
shed light on the ribosomal binding site and on the molec-
ular mechanism of action of this antibiotic. At the molec-
ular level, the data indicate that the primary mechanism by
which HygA inhibits protein synthesis resides in its ability
to bind the PTC, in a pocket that overlaps with the bind-
ing site of the aminoacyl-ribosyl moiety at the 3´end of the
A-site tRNA (Figure 3).
As seen in Figure 5A and B we show that although
HygA does not prevent the EF-Tu-dependent delivery of
the aminoacyl-tRNA to the ribosome, it interferes with the
correct positioning of the tRNA on the ribosome. Together
we interpret the structural and biochemical data to indicate
that HygA allows initial binding of the aminoacyl-tRNA to
the 30S A-site but prevents its subsequent accommodation
into the 50S A-site by sterically occluding the aminoacyl-
ribose moiety from binding within the PTC thus inhibit-
ing peptide bond formation. The interpretation that HygA
specifically impedes aminoacyl-tRNAbinding into the PTC
is in agreement with experiments showing that (i) HygA
blocks PT in assays using either the large 50S subunit or
the complete 70S ribosome and (ii) HygA inhibits binding
to the A site of acceptor mimics to the large subunit, de-
spite the lack of inhibition of larger substrates to the 70S
ribosome (Figure 5A) (10,12).
As seen in Figure 3 the region of HygA that is struc-
turally related to the aminoacyl-tRNA, does not bind as
deeply into the A-site as an aminoacyl-tRNA, but make
several interactions with PTCnucleotides that are compara-
ble to the A-site tRNA (Figure 3C–F) and positions critical
PTC nucleotides (i.e. U2506, U2585 and A2602) in confor-
mations distinct from the activated PTC conformation in-
duced by canonical A-site substrates (25,26,45). This HygA
induced state of the PTC could be an off-pathway confor-
mation unique to the drug or represent an intermediate state
normally acquired when canonical A-site substrates bind or
exit the A-site that is stabilized by the drug.
When the accessibility of the 23S rRNA nucleotides to
hydroxyl radical is probed in the presence and absence of
HygA, it becomes evident that the binding of HygA affects
not just the cleavage pattern of nucleotides located in its
vicinity, but also alters the chemical reactivity of nucleotides
distant from the binding pocket of HygA (Figure 4). Al-
though at this point we do not have any indication if the
alterations observed in the chemical probing experiments
may have a secondary role in HygA activity as in fact our
results indicate that the main mechanism of action of HygA
is to sterically clash with the accommodating A-site tRNA,
the altered reactivity of 23S rRNA nucleotides distant from
the binding pocket of HygA (i.e. in H89/90/92) could be
a side effect of it stabilizing an intermediate state normally
transitioned by canonical A-site substrates. In this respect,
it is noteworthy that the nucleotides displaying significant
changes in reactivity cluster in strategic regions of four he-
lices, H89/H90/H92/H92a (Figure 4) which on the basis of
biochemical (48), mutagenesis (49) andmolecular dynamics
studies (50), have been suggested to function as a commu-
nication channel between the PTC and GAR allowing for
coordination of the elongation factors EF-Tu and EF-G as
a function of the substrates present in and conformation of
the PTC (Supplementary Figure S4). A structural basis for
the alternation in hydroxyl radical accessibility cannot be
extrapolated from the presented structure given that differ-
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ences can be due to slight changes in the conformation or
dynamics of the bases that are not easily assessed in X-ray
crystallographic maps at the current resolution.
Previous experiments indicated that the binding site of
HygA overlaps and/or is incompatible with the binding of
other A-site targeting antibiotics like chloramphenicol, lin-
comycin and macrolides that possess a disaccharide at po-
sition 5 of the lactone ring, while the interaction of HygA
was found to be compatible with the binding of macrolides
that possess a monosaccharide at position 5 of the lactone
ring and do not inhibit the PT reaction (10,11). The 50S–
HygA structure presented here allows one to rationalize the
compatibility between these various drugs.
For example, it has been suggested that HygA shares
a binding site with chloramphenicol and lincomycin (10).
When the 50S–HygA structure is aligned with that of
chloramphenicol (CAM; PDB accession code: 1YJN) (51)
and clindamycin (CLY), a semisynthetic derivative of lin-
comycin (PDB accession code: 3OH5) (52,53), CAM and
CLY clash with the furanosyl and cinnamic acid moieties
of HygA (Supplementary Figure S3A and B). When in-
teractions of CAM with the ribosome are compared with
those of HygA, the latter outnumbers the former both in
polar and non-polar contacts (Supplementary Figure S3B–
E), keeping in line with the finding that HygA binds more
strongly to the ribosome and is amore potent inhibitor than
CAM (Figure 6A, (10)). Interestingly, although HygA and
CAM completely overlap for their binding pocket (Supple-
mentary Figure S3B), they differ in the specific interactions
with the rRNA (Supplementary Figure S3C–E) such that
a 23S rRNA mutation, G2061A (47), confers resistance to
CAM but not HygA (Figure 6B).
Concerning the macrolide antibiotics it has been ob-
served that they interfere with the binding of HygA to a
greater extent if a disaccharide is linked to position 5 of the
lactone ring (11). Superpositioning the 50S–HygA structure
with that of representative macrolides (Supplementary Fig-
ure S5) (54), allows one to rationalize these observations
(11). For example, the mycarose moiety in the disaccharide
extension of both carbomycin and spiramycin (PDB acces-
sion codes: 1K8A and 1KD1, respectively; (54)) encroaches
on the HygA binding site (Supplementary Figure S5B and
C). In the case of spiramycin the overlap mainly concerns
the furanose moiety while in the case of carbomycin the
overlap extends to both the furanosyl and cinnamic acid
moieties of HygA (Supplementary Figure S5B and C). This
is in good agreement with the observed ability of spiramycin
to reduce the binding of HygA while carbomycin com-
pletely prevents it although both drugs contain a disaccha-
ride in position 5 of the lactone ring (11). On the contrary,
erythromycin, which has only amonosaccharide at the posi-
tion 5 of the lactone ring and therefore does not extend into
the PTC, does not overlap withHygA (PDB accession code:
3OFR; Supplementary Figure S5D; (53)) and shows com-
patible bindingwithHygA (Supplementary Figure S5Dand
(11)). This understanding is important for designing new
antibiotics based on the HygA and/or macrolide backbone.
The presented HygA structure is largely consistent with
previous work detailing the drugs structure-activity rela-
tionships. Namely, such studies show that the furanosemoi-
ety can be substituted with short lipophilic chains (8,55,56),
which reflects the fact that although contributing to the in-
teraction of the drug with the ribosome this moiety does
not overlap with the A-site substrate and thus does not
directly play a role in drug’s inhibiting activity. If the fu-
ranose moiety is maintained, the tight packing of the 2′′
and 3′′ hydroxyl groups with the walls of the pocket is in
agreement with previous work showing that the 3′′ OH
is essential (55) and the 2′′ OH is phosphorylated in the
HygA producing organism in one of several possible mech-
anisms of self-resistance (14). Furthermore the acetyl group
of the furanose moiety is amendable to modification (as
seen with compounds 5′′-dihydrohygromycin A) (57), which
is in agreement with the fact that this group extends into
the lumen of the ribosomal tunnel. In the cinnamic acid
moiety the strict steric requirements imposed on active sub-
stituents (8,58,59) is supported by the structure which indi-
cates this moiety is tightly surrounded on one face by the
23S rRNA and on the other by the P-site bound tRNA (as
inferred by aligning structures harboring P-site substrates
to that of the HygA structure). The observation by Pala-
niappan et al. (60) that desmethylhygromycin and methoxy-
hygromycin display an in vitro activity comparable to HygA
suggests that the ring structure of the methylenedioxy in
the aminocyclitol moiety is not strictly required for ribo-
some interaction. In fact the potential hydrogen bonds ob-
served between O5 with the amine N4 of C2573 and be-
tween O4 with the amine N2 of G2583 in the HygA-50S
structure would be similarly possible for the desmethylhy-
gromycin and methoxyhygromycin derivatives.
In conclusion this study indicates that HygA has a dis-
tinct ribosomal interaction, induces a unique PTC confor-
mation and thus employs a distinctive molecular strategy to
block protein synthesis. This information is critical to de-
veloping new antibiotics with improved pharmacokinetics
and reduced sensitivities to existing resistance mechanisms
by building on existing anti-infective frameworks.
NOTES ADDED IN PROOF
During the revision of the present article, a study describ-
ing the structures and mechanism of action of HygA on the
ribosome was reported (61). The general conclusion of the
two independent articles is essentially the same concerning
HygA’s mechanism of action. Moreover, a comparison of
the HygA-bound structures of the D. radiodurans 50S sub-
unit (this study) and E. coli 70S ribosome in two different
states (70S alone, PDB accession code: 4Z3R and 70S plus
mRNA, A- and P-site tRNAs, PDB accession code: 4Z3Q;
Polikanov et al. (61)) reveals that the binding site of the an-
tibiotic is nearly identical independent of the organism used
for the ribosome preparation, the use of 50S subunits or 70S
ribosomes or the presence of mRNA and tRNAs (Supple-
mentary Figure S6). One difference, however, concerns the
conformation of A2602 and A2062. As these residues are
positioned differently in the structures, e.g. A2602 acquires
a different conformation in each of the models reported,
while HygA retains the same binding position through all
three complexes, they likely play a less important role for
the binding of the antibiotic and their different positioning
rather reflects their high sensitivity to the presence of PTC
substrates (25,62).
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Table 1. Data Collection and refinement Statistics
Complex 50S apo 50S–HygA
PDB accession code 5DM6 5DM7
Data collection statistics
Space group I222 I222
Cell dimensions, A˚ (a, b, c) 169.90, 410.76,
696.12
169.82, 411.54,
695.65
Resolution range, A˚ 59.3–2.90
(3.06–2.90)
59.3–3.00
(3.16–3.00)
Resolution where I/I = 2, A˚ 3.2 3.7
No. of observed reflections 11 664 835
(1 754 909)
2 197 039
(315 299)
No. of unique reflections 531 662
(78 466)
479 454
(68 449)
Multiplicity 21.9 (22.3) 4.58 (4.60)
Completeness,% 99.8 (99.6) 99.5 (99.1)
Rmerge,% 24.1 (786.2) 21.5 (562.3)
I/I 10.38 (0.71) 6.28 (0.33)
CC(1/2),% 99.9 (47.8) 99.8 (18.5)
Wilson B-factor, A˚2 78.94 66.56
Refinement statistics
Rwork/Rfree,% 24.1/28.2 26.5/31.5
No. of atoms
RNA 62 274 62 274
Protein 27 162 27 162
Ligand 0 36
Ions 198 197
RMSD
Bond lengths, A˚ 0.014 0.027
Bond angles, ◦ 2.323 2.407
Values in parentheses refer to the highest resolution bin.
Each dataset was obtained from a single crystal.
The only main difference between the two studies con-
cerns the specific stereochemistry of the aminocyclitol moi-
ety of HygA (Supplementary Figure S6). This moiety has
been modeled in a neo configuration in our study and in
a myo configuration in the work of Polikanov et al. (Sup-
plementary Figure S6; (61)). From the discovery and ini-
tial characterization of HygA in the 1950’s chemical and
spectroscopic analysis have indicated that the aminocycli-
tol moiety is in the neo-configuration (5–7,38,63–67) as de-
picted in Supplementary Figure S1 and in the final model
presented in this study. Indeed the neo-configuration is also
presented in the schematic drawing of HygA in Figure 2E
of Polikanov et al. (61) but it is not maintained in the de-
posited structures (PDB accession code: 4Z3Q and 4Z3R).
After communicating and sharing with Polikanov et al.,
the HygA structure we are reporting in this study, they ac-
knowledged the appropriateness of the neo configuration
and will accordingly update the deposited PDB entries as
the neo configuration and indeed the HygA structure we
are reporting nicely fits and results in good agreement also
with their experimental data (Polikanov, Wilson and Blan-
chard, personal communication). It is important to note
that when compared to the myo configuration, the neo-
configuration in our structure yields a different geometry
and a slightly different pattern for the specific interactions
of HygA with the ribosome; most obviously the potential
interactions observed in this study betweenG2583 (N2) and
C2573 (N4) with the oxygen atoms in the methylenedioxy
ring of the aminocyclitol moiety (Figure 2C) which, are not
in hydrogen bonding distance with any ribosomal element
in the original model reported by Polikanov et al. (61). In
this context, we would like to comment that as indicated
by Polikanov et al. (61) initial studies on the function of
the methylenedioxy ring in HygA have suggested that this
bridge could be important for the antimicrobial activity of
HygA due to its ability to bias the aminocyclitol ring to-
ward the twisted boat conformation (58,59,64). This hy-
pothesis had been inferred from (i) spectroscopic and chem-
ical analysis of HygA and its derivatives, which support the
twisted boat conformation for HygA in solution (38) and
(ii) the observation that methoxyhygromycin, which differs
from HygA by the opening of the methylendioxy ring, ac-
quires in solution a chair conformation and has an over-
all lower antimicrobial activity compared to HygA (68). In
our complex, HygA readily acquires a chair like conforma-
tion. This result indirectly supports more recent in vivo and
in vitro studies on the function of the methylenedioxy ring
which confirm its importance for the potency of the drug
but points at its function in affecting the antibiotic uptake
into the cell rather than the inhibition of the peptidyltrans-
ferase center (60).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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